Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Trial Profile

A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Azacitidine; Decitabine; Posaconazole
  • Indications Acute myeloid leukaemia
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 31 May 2020 Results (n=197: data cutoff date: Aug 2018) of an analysis from two clinical studies: NCT02203773 and NCT02287233 assessing rapidity and likelihood of response to Venetoclax treatments presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 20 Mar 2020 Planned End Date changed from 26 Mar 2021 to 27 Sep 2021.
    • 20 Mar 2020 Planned primary completion date changed from 26 Mar 2021 to 27 Sep 2021.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top